Bioxytran, Inc.
BIXT
$0.07
$0.00-1.94%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.24M | 1.04M | 1.52M | 2.11M | 2.12M |
| Depreciation & Amortization | 11.50K | 8.80K | 7.80K | 7.90K | 8.80K |
| Other Operating Expenses | -3.00K | -3.00K | -- | -- | -- |
| Total Operating Expenses | 1.74M | 1.58M | 1.97M | 2.23M | 2.75M |
| Operating Income | -1.74M | -1.58M | -1.97M | -2.23M | -2.75M |
| Income Before Tax | -2.12M | -2.23M | -2.92M | -2.14M | -2.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.12 | -2.23 | -2.92 | -2.14 | -2.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.30K | 13.30K | 13.30K | 26.60K | 35.10K |
| Net Income | -2.10M | -2.21M | -2.91M | -2.12M | -2.64M |
| EBIT | -1.74M | -1.58M | -1.97M | -2.23M | -2.75M |
| EBITDA | -1.72M | -1.57M | -1.96M | -2.22M | -2.75M |
| EPS Basic | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 359.60M | 397.00M | 484.77M | 559.38M | 614.02M |
| Average Diluted Shares Outstanding | 359.60M | 397.00M | 484.77M | 559.38M | 614.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |